Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection
Europace · 2023
DOI: 10.1093/europace/euad306 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Europace, 2023. Verfasst von Stefan Borov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Klinikum Freising, Alois-Steinecker-Straße 18, Freising 85354, Germany. Hauptthemen laut MEDLINE: Anti-Infective Agents, Defibrillators, Implantable, Heart Diseases, Pacemaker, Artificial. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: TauroPace™., TauroPace™.
Abstract (Originalsprache)
Aims
TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. Methods and results The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802).
Conclusion
TauroPace is safe but more effective than H2O2 in reducing CIED infection. Clinical trial registration ClinicalTrials.gov Identifier: NCT05576194
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Klinikum Freising, Alois-Steinecker-Straße 18, Freising 85354, Germany.
- Medical Faculty, Christian-Albrechts University, Christian-Albrechts-Platz 4, Kiel 24118, Germany.
- Institute of Life Science, Hochschule Bremerhaven, An der Karlstadt 8, Bremerhaven 27568, Germany.
- Krankenhaus Landshut Achdorf, Achdorfer Weg 3, Landshut 84036, Germany.
- Department of Cardiology, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK.
- Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany.
ORCID-Profile: Stefan Borov, Benito Baldauf, Herribert Pavaci, Bernhard Zrenner, Julinda Mehilli, Reinhard Vonthein, Hendrik Bonnemeier
Förderung
- TauroPace™.
- TauroPace™
Zitieren
APA
Borov, S., Baldauf, B., Henke, J., Pavaci, H., Perani, A., Zrenner, B., Dietl, J., Mehilli, J., Lau, E. W., Vonthein, R., & Bonnemeier, H. (2023). Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection. Europace. https://doi.org/10.1093/europace/euad306
Vancouver
Borov S, Baldauf B, Henke J, Pavaci H, Perani A, Zrenner B, et al. Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection. Europace. 2023. doi:10.1093/europace/euad306
BibTeX
@article{Borov2023,
author = {Borov, Stefan and Baldauf, Benito and Henke, Jana and Pavaci, Herribert and Perani, Arben and Zrenner, Bernhard and Dietl, Josef and Mehilli, Julinda and Lau, Ernest W and Vonthein, Reinhard and Bonnemeier, Hendrik},
title = {Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection},
journal = {Europace},
year = {2023},
doi = {10.1093/europace/euad306}
}
EUVIMED